EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Consensus Statement on Metabolic Dysfunction‐Associated Steatotic Liver Disease in Children and Adolescents From the Joint TASL ‐ TSPGHAN Expert Committee

Yu‐Cheng Lin, Fang‐Min Liao, Hsun‐Ching Chao, An‐Chyi Chen, Yung‐Ming Jeng, Chieh‐Chung Lin, Mao‐Meng Tiao, Yao‐Jong Yang, Chun‐Yan Yeung, Huey‐Ling Chen, Yen‐Hsuan Ni

JGH Open · 2025-06 · 9 (6)

DOI: 10.1002/jgh3.70137 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Background and Objective Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most prevalent chronic liver condition in children and adolescents, driven by the global rise in pediatric obesity. In this consensus statement by the Taiwan Association for the Study of the Liver (TASL) and the Taiwan Society of Pediatric Gastroenterology, Hepatology, and Nutrition (TSPGHAN), we highlight the unique clinical challenges in diagnosing and managing this condition in Asian children. Methods This consensus was developed by expert members of TASL and TSPGHAN through a comprehensive review of current literature and clinical practice. Key topics included prevalence, screening policies, diagnostic criteria, disease characteristics, and management strategies relevant to pediatric MASLD. Results We emphasize the rising prevalence of pediatric MASLD, which correlates strongly with obesity but often remains underdiagnosed due to the lack of screening policy for at‐risk individuals and variations in diagnostic criteria. This review also discusses the distinct natural history and histopathological features of pediatric MASLD, underscoring the critical need for a greater understanding of its long‐term outcomes. Currently, liver enzymes and ultrasonography are commonly used for screening and diagnosis, though these methods have limitations. The diagnostic imaging and novel non‐invasive biomarkers specifically tailored for pediatric MASLD are in urgent need. Clinical management continues to rely on lifestyle interventions, with no pharmacological treatments currently approved for pediatric MASLD. Conclusion Effective management of pediatric MASLD requires a comprehensive approach to risk assessment, early detection, and intervention, tailored to the disease's unique pathophysiology in children.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →